维昇药业-B（02561）8月17日公告称，公司董事会已排期于2026年8月27日（星期四）召开会议，审议并通过本集团截至2026年6月30日止六个月的中期业绩，并处理其他相关事项。
公告显示，董事会目前由执行董事卢安邦先生、非执行董事付山先生、曹弋博先生、Roy Paul Khoury先生、Sherrie Lynn Glass女士及Michael J. Chang先生，以及独立非执行董事YAO Zhengbin (Bing)博士、陈炳钧先生、倪虹女士和张勍先生组成。
公司强调，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责，对其准确性或完整性亦不发表任何声明，并且明确表示不承担任何因依赖该公告而产生的损失责任。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.